Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel #lymphoma #lymsm https://t.co/
RT @Lymphoma_Papers: Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later…
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel #lymphoma #lymsm https://t.co/
RT @CARTTherapy: MAIC of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory LBCL: liso-…